<DOC>
	<DOCNO>NCT00588185</DOCNO>
	<brief_summary>This study use PET scan , type x-ray test use radiotracer , see whether scan may better able find place body prostate cancer may spread .</brief_summary>
	<brief_title>18F-Fluoro-2-Deoxy-D-Glucose -18F Dihydro-Testosterone Pet Imaging Patients With Progressive Prostate Cancer</brief_title>
	<detailed_description>Our preliminary study show whole body FDG-PET imaging identifies area abnormal metabolism majority tumor sit patient progressive disease change FDG accumulation parallel change PSA treatment . This suggest change FDG metabolism may provide early assessment treatment outcome . In previous work establish methodology examine radiotracer patient progressive disease abnormal imaging study , apply clinical state non-castrate castrate metastatic disease . This design characterize : 1 ) Evaluation uptake site-by-site basis relation conventional study 2 ) Standardization uptake value tumor relative normal organ 3 ) Controlling progression use standard measure progression include rise PSA , new enlarge lesion bone transaxial imaging , new symptom disease . In present study evaluate fluorinated dihydrotestosterone ( FDHT ) addition FDG . FDHT target AR show preliminary study visualize prostate cancer man . This study apply establish method investigate FDHT image patient progressive prostate cancer . In select case tumor available , study association FDHT accumulation AR expression .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Dihydrotestosterone</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Deoxyglucose</mesh_term>
	<criteria>Patients histologically confirm prostate cancer . Progressive disease manifest either : Imaging modality : Bone Imaging : New osseous lesion bone image ( bone scintigraphy NaF PET scan ) and/or MRI CT : An increase measurable soft tissue disease , appearance new site disease . Or Biochemical progression : A minimum three rise PSA value baseline obtain 1 week apart , 2 measurement 2 week apart . Visible lesion either CT , bone imaging , MRI consistent disease . Informed consent . Previous anaphylactic reaction either FDHT FDG Hepatic : Bilirubin &gt; 1.5 x upper limit normal ( ULN ) , AST/ALT &gt; 2.5 x ULN , albumin &lt; 2 g/dl , GGT &gt; 2.5 x ULN IF Alkaline phosphatase &gt; 2.5 x ULN Renal : Creatinine &gt; 1.5 x ULN creatinine clearance &lt; 60 mL/min</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Progressive Prostate Cancer</keyword>
	<keyword>[ 18F ] -Fluoro-2-Deoxy-D-Glucose</keyword>
	<keyword>[ 18F ] Dihydro-Testosterone</keyword>
	<keyword>Pet Imaging</keyword>
	<keyword>Pet scan</keyword>
	<keyword>00-095</keyword>
</DOC>